⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Klotho Protein and Gene Therapies
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-11-12 — Phase I Trial of a Single Administration of aKLmRNA-Mediated Protein Replacement Therapy: [mechanism-plausible — efficacy rationale only, not randomized human evidence] An open-label Phase I protocol at GARM Próspera describes a single intravenous AKL003 alpha-Klotho mRNA infusion in 20 planned healthy participants, assessing safety and exploratory aging markers including DNA methylation; the finding reports no outcome results and does not establish safety, healthspan benefit, or lifespan extension. [mechanism-plausible] (novelty: 4)
Open questions
Related
Contributing findings
Phase I Trial of a Single Administration of aKLmRNA-Mediated Protein Replacement Therapy
12-nov-2026
novelty 4
per-area 4
strengthens